- Home
- SHOT vs PULM Comparison
SHOT vs PULM Comparison
Compare SHOT & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- PULM
- Stock Information
- Founded
- SHOT 2018
- PULM 2003
- Country
- SHOT United States
- PULM United States
- Employees
- SHOT N/A
- PULM N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- SHOT Health Care
- PULM Health Care
- Exchange
- SHOT Nasdaq
- PULM Nasdaq
- Market Cap
- SHOT 30.4M
- PULM 33.2M
- IPO Year
- SHOT 2020
- PULM N/A
- Fundamental
- Price
- SHOT $0.47
- PULM $6.41
- Analyst Decision
- SHOT
- PULM
- Analyst Count
- SHOT 0
- PULM 0
- Target Price
- SHOT N/A
- PULM N/A
- AVG Volume (30 Days)
- SHOT 5.1M
- PULM 57.7K
- Earning Date
- SHOT 08-13-2025
- PULM 08-12-2025
- Dividend Yield
- SHOT N/A
- PULM N/A
- EPS Growth
- SHOT N/A
- PULM N/A
- EPS
- SHOT N/A
- PULM N/A
- Revenue
- SHOT $573,336.00
- PULM $1,921,000.00
- Revenue This Year
- SHOT N/A
- PULM N/A
- Revenue Next Year
- SHOT N/A
- PULM $134.88
- P/E Ratio
- SHOT N/A
- PULM N/A
- Revenue Growth
- SHOT 69.32
- PULM N/A
- 52 Week Low
- SHOT $0.23
- PULM $1.78
- 52 Week High
- SHOT $1.77
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- SHOT 59.24
- PULM 37.18
- Support Level
- SHOT $0.39
- PULM $6.28
- Resistance Level
- SHOT $0.56
- PULM $6.83
- Average True Range (ATR)
- SHOT 0.08
- PULM 0.35
- MACD
- SHOT 0.01
- PULM -0.07
- Stochastic Oscillator
- SHOT 66.23
- PULM 0.00
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).